NATICK, Mass. — Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, announced initial results from the combination of the Allurion Program with low-dose tirzepatide therapy aimed at optimizing muscle mass and adherence to GLP-1 treatments.
Seventy-six patients treated with the Allurion Smart Capsule were started on low-dose tirzepatide after completing the first 45 days of balloon therapy. Patients began at 2.5 mg and increased to no more than 5.0 mg over two months, notably lower than standard tirzepatide dosing, which can rise to 15 mg. Treatment continued for eight months, with final results recorded two months after discontinuation for a total follow-up period of 12 months. All patients were monitored through Allurion’s AI-powered Virtual Care Suite.
At 12 months, patients achieved an average total body weight loss of 23 percent, and lean body mass as a percentage of total body weight rose from 62 percent to 70 percent—a 14 percent increase. No patients discontinued the therapy early, and adherence to tirzepatide remained at 100 percent throughout the study.
“These results provide additional data that a combination approach with the Allurion Smart Capsule and GLP-1 medications has several advantages,” said Dr. Luigi Flagiello, an expert in minimally invasive obesity care at Clinica Ruesch who oversaw the case series. “By combining these two therapies that have distinct physiological mechanisms of action and following patients closely using AI-powered virtual care, we can unlock increased weight loss while still increasing lean mass. By using lower doses of GLP-1s, we also show exceptional adherence to the GLP-1, which can lead to longer term weight maintenance.”
Previous research in patients treated with GLP-1 therapies has shown reductions in lean mass of roughly 40 percent of total weight lost, and found that about 30 percent of patients discontinue GLP-1 therapy within one month and 58 percent discontinue before reaching a meaningful clinical benefit, often due to side effects, the need for dose increases, and cost challenges.
A recent study published in JAMA Internal Medicine reported that greater weight regain after tirzepatide withdrawal was associated with reversal of improvements in waist circumference, blood pressure, lipids, glycemic control and insulin resistance.
“We now have initial data for both low-dose semaglutide and tirzepatide in combination with the Allurion Program that addresses two significant challenges for GLP-1s—muscle wasting and lack of adherence,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “A combination approach that leverages Allurion’s full program—which includes the Smart Capsule, our AI-powered Virtual Care Suite, and our behavior change program—appears to be a compelling solution. We look forward to validating these results in a prospective clinical trial setting and are optimistic that this could become a new standard of care for patients who want metabolically healthy weight loss.”
Additional data from the case series will be presented at upcoming medical meetings.
